Our study identified MDM2 as an important target of NAT10 and revealed an ac4C modification-dependent mechanism critical to MDM2 activation in GC, creating the possibility to develop therapeutic strategies against GC by targeting ac4C modifications and its regulator, NAT10. This evidence concerns the gene NAT10 and gastric cancer.